PharmaEngine, Inc.
4162
Rank in Stocks
#16024
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and... PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
Share Price
$1.61
Last synced: 2026-11-10
Market Cap
$231.70M
Change (1 day)
1.34%
Change (1 year)
-27.03%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PharmaEngine, Inc. (4162)
Category
Healthcare
Operating Margin for PharmaEngine, Inc. (4162)
Operating Margin as of November 2026 TTM: 47.32%
According to PharmaEngine, Inc.'s latest financial reports, its current operating margin (TTM) is 47.32%. At the end of 2025 the company had an operating margin of 46.68%.
Operating Margin history for PharmaEngine, Inc. from 2008 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 47.32% | 1.37% |
| 2025 | 46.68% | -42.63% |
| 2024 | 81.37% | 125.34% |
| 2023 | 36.11% | -16.43% |
| 2022 | 43.21% | -21.93% |
| 2021 | 55.35% | -27.82% |
| 2020 | 76.68% | 638.73% |
| 2019 | 10.38% | -28.22% |
| 2018 | 14.46% | -79.86% |
| 2017 | 71.80% | 0.83% |
| 2016 | 71.21% | 10.35% |
| 2015 | 64.53% | 109.44% |
| 2014 | 30.81% | -108.26% |
| 2013 | -372.95% | -1,485.40% |
| 2012 | 26.92% | -64.44% |
| 2011 | 75.71% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.18% |
US
|
|
| -149.01% | -103.15% |
US
|
|
| 25.57% | -99.46% |
AU
|
|
| 31.23% | -99.34% |
BE
|
|
| 29.35% | -99.38% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about PharmaEngine, Inc.'s operating margin
What is PharmaEngine, Inc.'s operating margin?
PharmaEngine, Inc.'s operating margin is 47.32%, as of Nov 2026.
What was PharmaEngine, Inc.'s operating margin in 2025?
In 2025, PharmaEngine, Inc.'s operating margin was 46.68%, compared with 81.37% in 2024.
How has PharmaEngine, Inc.'s operating margin changed since 2020?
From 2020 to 2025, PharmaEngine, Inc.'s operating margin was highest in 2024 (81.37%) and lowest in 2023 (36.11%).
How does PharmaEngine, Inc.'s operating margin compare with similar companies?
PharmaEngine, Inc.'s operating margin (47.32%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.